The private equity industry is rapidly embracing generative AI, leveraging its potential to drive growth, increase efficiency, and gain a competitive edge. However, as AI integration deepens, firms must be aware of the potential liabilities and complications that come with it. From regulatory risks to ethical considerations, it’s crucial for private equity professionals to develop a responsible approach to AI adoption, understanding its exposures within their portfolios and ensuring they have the right insurance programs in place to mitigate risks.
AI tools are already delivering critical value to private equity firms, facilitating comprehensive deal due diligence, better-informed valuations, and increased efficiency in logistics and data analysis. However, regulators are hyper-focused on private equity, and firms must examine their internal processes, understand potential AI-related risks, and have the right insurance program to mitigate their risk. This includes developing an organizational philosophy on responsible AI use, addressing potential regulatory quagmires such as AI washing, antitrust, and ethical considerations.
Firms must also understand AI exposures within their portfolios, including biometric data applications and potential violations of biometric privacy laws. Effective insurance programs are crucial in case of unforeseen lawsuits or regulatory actions, and firms must evaluate their coverage to ensure it addresses AI risks.
